PCVX
Vaxcyte, Inc.
There isn't enough reported data to score PCVX yet.
PCVX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
PCVX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
PCVX PE Valuation
PCVX has no meaningful PE right now: it lost money over the past year.
PCVX Forward outlook
There aren't enough analyst estimates for PCVX to show an outlook.
PCVX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$8.07 | -$3.23 |
| Q2 2026 | -$7.64 | -$3.53 |
| Q1 2026 | -$6.89 | -$2.90 |
| Q4 2025 | -$5.63 | -$1.83 |
| Q3 2025 | -$4.84 | -$0.23 |
| Q2 2025 | -$4.11 | +$0.58 |
| Q1 2025 | -$3.99 | +$0.30 |
| Q4 2024 | -$3.80 | +$0.34 |
PCVX is still losing money, but less than at its worst: $8.07 per share over the past year, against $10.38 at its worst in late 2019.
PCVX Quarterly Revenue
PCVX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$227.4M | -$80.3M |
| Q2 2026 | -$236.8M | -$113.8M |
| Q1 2026 | -$282.7M | -$111M |
| Q4 2025 | -$227.5M | -$112.1M |
| Q3 2025 | -$147.1M | -$81.5M |
| Q2 2025 | -$123M | +$6.2M |
| Q1 2025 | -$171.7M | -$6.9M |
| Q4 2024 | -$115.4M | +$18.6M |
PCVX has burned cash in almost every quarter: −$974M over the past year, against −$557M the year before.
PCVX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.1% | +4.4M shares |
| 1 year | +9.3% | +12.7M shares |
| 3 years | +46% | +47.2M shares |
| 5 years | +185% | +96.7M shares |
| Available history | +489% | +124M shares |
PCVX has 149M diluted shares, up 9.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | — |
| Q4 2019 | — |
PCVX Net Leverage
PCVX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PCVX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.5 | Neutral |
| Stochastic | 27.1 | Neutral |
PCVX's weekly RSI is 57 (neutral) and its Stochastic is 27 (neutral).
PCVX PE vs Healthcare Sector
PCVX has no meaningful PE right now: it lost money over the past year.
PCVX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $62.3 | 3.8% above |
| 20 week MA | $59.9 | 8% above |
| 50 week MA | $55.7 | 16% above |
| 100 week MA | $52.6 | 23% above |
| 200 week MA | $58.7 | 10% above |
PCVX has climbed back above all five of its weekly moving averages, and it's now 10% above its 200-week average.
PCVX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.2 | $28.0 | +6.9% |
| 2021 | $28.0 | $24.2 | -14% |
| 2022 | $24.2 | $46.7 | +93% |
| 2023 | $46.7 | $62.8 | +35% |
| 2024 | $62.8 | $81.0 | +29% |
| 2025 | $81.0 | $47.0 | -42% |
| 2026 YTD | $47.0 | $64.7 | +38% |
PCVX has finished higher in four of the last six years. It's up 38% so far in 2026.